Sweden
· Delayed Price · Currency is SEK SynAct Pharma AB Statistics
Total Valuation
SynAct Pharma AB has a market cap or net worth of SEK 364.65 million. The enterprise value is 303.28 million.
| Market Cap | 364.65M |
| Enterprise Value | 303.28M |
Important Dates
The next estimated earnings date is Tuesday, September 3, 2024.
| Earnings Date | Sep 3, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SynAct Pharma AB has 41.30 million shares outstanding. The number of shares has increased by 29.58% in one year.
| Shares Outstanding | 41.30M |
| Shares Change (YoY) | +29.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 16.67% |
| Owned by Institutions (%) | 10.34% |
| Float | 21.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.95 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.83 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.77.
| Current Ratio | 4.25 |
| Quick Ratio | 3.60 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -47.17 |
Financial Efficiency
Return on equity (ROE) is -77.46% and return on invested capital (ROIC) is -23.81%.
| Return on Equity (ROE) | -77.46% |
| Return on Assets (ROA) | -19.01% |
| Return on Capital (ROIC) | -23.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -33.19M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.80% in the last 52 weeks. The beta is 0.68, so SynAct Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -90.80% |
| 50-Day Moving Average | 8.34 |
| 200-Day Moving Average | 7.78 |
| Relative Strength Index (RSI) | 56.53 |
| Average Volume (20 Days) | 72,445 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -82.07M |
| Pretax Income | -168.35M |
| Net Income | -165.96M |
| EBITDA | n/a |
| EBIT | -82.07M |
| Earnings Per Share (EPS) | -4.68 |
Balance Sheet
The company has 62.80 million in cash and 1.44 million in debt, giving a net cash position of 61.36 million or 1.49 per share.
| Cash & Cash Equivalents | 62.80M |
| Total Debt | 1.44M |
| Net Cash | 61.36M |
| Net Cash Per Share | 1.49 |
| Equity (Book Value) | 186.99M |
| Book Value Per Share | 4.53 |
| Working Capital | 68.60M |
Cash Flow
| Operating Cash Flow | -82.39M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SynAct Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.58% |
| Shareholder Yield | -29.58% |
| Earnings Yield | -52.97% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |